A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Phase 2

Terminated

Conditions: Melanoma
Small Cell Lung Cancer
Non-small Cell Lung Cancer, Non-squamous
Prostate Cancer
Non-small Cell Lung Cancer, Squamous
Esophageal Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: ladiratuzumab vedotin
Drug: pembrolizumab

Registration Number: NCT04032704

Lead Sponsor: Seagen Inc.

Brief Summary: This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.

Detailed Description: This trial is designed to assess the antitumor activity, safety, and tolerability of LV alone and with pembrolizumab, for the treatment of solid tumors. Participants with the following advanced solid tumors will be enrolled:

Cohort 1: small cell lung cancer (SCLC) Cohort 2: non-small cell lung cancer-squamous (NSCLC-squamous) Cohort 3: non-small cell lung cancer-nonsquamous (NSCLC-nonsquamous) Cohort 4: head and neck squamous cell carcinoma (HNSCC) Cohort 5: esophageal squamous cell carcinoma (esophageal-squamous) Cohort 6: gastric and gastroesophageal junction (GEJ) adenocarcinoma Cohort 7: castration-resistant prostate cancer (CRPC) Cohort 8: melanoma

Participants will continue to receive study treatment until disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the sponsor, pregnancy, or death, whichever comes first.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 205

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Part A: Non-randomized LV monotherapy	ladiratuzumab vedotin	Monotherapy dosing schedule 1.
Part C - Arm 3: Randomized LV combination therapy	pembrolizumab	Combination dosing schedule 2.
Part B: Non-randomized LV monotherapy	ladiratuzumab vedotin	Monotherapy dosing schedule 2.
Part C - Arm 2: Randomized LV combination therapy	pembrolizumab	Combination dosing schedule 1.
Part C - Arm 1: Randomized LV monotherapy	ladiratuzumab vedotin	Monotherapy dosing schedule 3.
Part C - Arm 2: Randomized LV combination therapy	ladiratuzumab vedotin	Combination dosing schedule 1.
Part C - Arm 3: Randomized LV combination therapy	ladiratuzumab vedotin	Combination dosing schedule 2.

Primary Outcome Measures

Name	Time	Method
Part A: Confirmed Objective Response Rate (ORR) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)	From the first dose of study treatment until the first documented CR or PR or new anticancer therapies or death, whichever occurred first (maximum up to 8.3 months)	Confirmed ORR was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than (\<) 10 millimeter (mm). PR was defined as more than or equal to (\>=) 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants who did not have at least 2 post-baseline response assessment (initial response and confirmation scan) were counted as non-responders.
Part B: Confirmed ORR as Determined by Investigator According to RECIST v1.1	From the first dose of study treatment until the first documented CR or PR or new anticancer therapies or death, whichever occurred first (maximum up to 34.7 months for 1.25 mg/kg and 5.7 months for 1 mg/kg dose level)	Confirmed ORR was defined as the percentage of participants with a confirmed CR or PR per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as \>= 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants who did not have at least 2 post-baseline response assessment (initial response and confirmation scan) were counted as non-responders.
Part B: Confirmed Prostate-Specific Antigen (PSA) Response Rate as Determined by Investigator According to Prostate Cancer Clinical Trials Working Group 3 (PCWG3) Criteria, for Prostate Cancer	From the first dose of study treatment up to the date of last response assessment (maximum up to 13.5 months)	Confirmed PSA response rate was defined as the percentage of participants with a reduction from baseline PSA level of at least 50%, measured twice \>= 3 weeks apart. PSA progression was defined as per PCWG3 criteria- a) if a participant presented first a decline from baseline, progression was defined as the first PSA increase that was \>=25% and \>=2 nanograms per milliliter (ng/mL) above the nadir, and which was confirmed by a consecutive second value \>=3 weeks later that fulfilled the same criteria (that is, a confirmed rising trend); b) if a participant did not present a decline from baseline, progression was defined as the first PSA increase that was \>=25% and \>=2 ng/mL increased from baseline beyond 12 weeks.

Secondary Outcome Measures

Name	Time	Method
Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), Treatment Related TEAEs and >= Grade 3 TEAE	From start of study treatment up to 30 days after last dose of study treatment (maximum up to 37.5 months)	An adverse event (AE) was any untoward medical occurrence in a participant/ clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. AEs included both SAEs ad all non-SAEs. TEAEs were defined as newly occurring (not present at baseline)/worsening after first dose of study treatment. TESAEs were any untoward medical occurrence at any dose that: suspected to cause death; life-threatening; required hospitalization; persistent/significant disability/incapacity \& may cause congenital anomaly/birth defect. Treatment related TEAEs were related to study treatment and relatedness was judged by investigator. TEAEs were graded according to National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 4.03 (grade 1= mild, grade 2= moderate, grade 3= severe and grade 4= life-threatening).
Part B: Number of Participants With TEAEs, TESAEs, Treatment Related TEAEs and >= Grade 3 TEAE	From start of study treatment up to 30 days after last dose of study treatment (maximum up to 37.5 months)	An AE was any untoward medical occurrence in a participant, or a clinical investigational participant administered a medicinal product, and which does not necessarily have a causal relationship with this treatment. AEs included both SAEs ad all non-SAEs. TEAEs were defined as newly occurring (not present at baseline) or worsening after first dose of study treatment. TESAEs were any untoward medical occurrence at any dose that: suspected to cause death; life-threatening; required hospitalization; persistent or significant disability or incapacity and may cause congenital anomaly or birth defect. Treatment related TEAEs were related to study treatment and relatedness was judged by investigator. TEAEs were graded according to NCI-CTCAE v4.03 (grade 1= mild, grade 2= moderate, grade 3= severe and grade 4= life-threatening).
Part A: Confirmed Investigator Determined Disease Control Rate (DCR) According to RECIST v1.1	From the first dose of study treatment until the first documented CR, PR or SD or new anticancer therapies or death, whichever occurred first (maximum up to 4.1 months)	DCR was defined as percentage of participants who achieved confirmed and unconfirmed CR or PR per RECIST v1.1 or met stable disease (SD) criteria at least once after start of study treatment at minimum interval of 5 weeks. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as \>= 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference smallest sum diameters while on study. PD: at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (this included baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 0.5 cm. Appearance of one or more new lesions was also considered progression.
Part B: Confirmed Investigator Determined DCR According to RECIST v1.1	From the first dose of study treatment until the first documented CR, PR or SD or new anticancer therapies or death, whichever occurred first (maximum up to 5.5 months for 1.25 mg/kg and 1.5 months for 1 mg/kg dose level)	DCR was defined as percentage of participants who achieved confirmed and unconfirmed CR or PR per RECIST v1.1 or met SD criteria at least once after start of study treatment at a minimum interval of 5 weeks. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as \>= 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: At least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 centimeter (cm). Appearance of one or more new lesions was also considered progression.
Part A: Confirmed Investigator Determined Duration of Response (DOR) According to RECIST v1.1	From the first documentation of CR or PR to PD or death or censoring whichever occurred first (maximum up to 5.7 months)	DOR:time from 1st documentation of OR(confirmed CR/PR per RECIST Version 1.1) to 1st documentation of PD/death due to any cause,whichever occurred first.CR:disappearance of all target lesions.Any pathological lymph nodes must have reduction in short axis to \<10 mm.PR:\>=30 % decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. Participants do not have PD and are still on study at time of analysis/are removed from study prior to documentation of PD were censored at last disease assessment documenting absence of PD. Participants who started new anticancer treatment prior to documentation of PD were censored at last disease assessment prior to start of new treatment.PD:at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study.In addition to relative increase of 20%, sum must demonstrate absolute increase of 0.5 cm.Appearance of one/more new lesions was considered progression. Kaplan-Meier method was used.
Part B: Confirmed Investigator Determined DOR According to RECIST v1.1	From the first documentation of CR or PR to PD or death or censoring whichever occurred first (maximum up to 32.0 months for 1.25 mg/kg and 4.2 months for 1 mg/kg dose level)	DOR:time from 1st documentation of OR(confirmed CR/PR per RECIST Version 1.1) to 1st documentation of PD/death due to any cause,whichever occurred first.CR:disappearance of all target lesions.Any pathological lymph nodes must have reduction in short axis to \<10 mm.PR:\>=30 % decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. Participants do not have PD and are still on study at time of analysis/are removed from study prior to documentation of PD were censored at last disease assessment documenting absence of PD. Participants who started new anticancer treatment prior to documentation of PD were censored at last disease assessment prior to start of new treatment.PD:at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study.In addition to relative increase of 20%, sum must demonstrate absolute increase of 0.5 cm.Appearance of one/more new lesions was considered progression. Kaplan-Meier method was used.
Part B: Confirmed Investigator Determined PSA-DOR, for Prostate Cancer	From the first documentation of CR or PR to PD or death or censoring whichever occurred first (maximum up to 3 months)	PSA-DOR was defined as the time from the first documentation of PSA response (subsequently confirmed at least 3 weeks apart) to the first documentation of PSA progression or death due to any cause, whichever occurred first. Confirmed PSA response rate was defined as the percentage of participants with a reduction from baseline PSA level of at least 50%, measured twice \>= 3 weeks apart. Participants who do not have PD and are still on study at the time of an analysis or who are removed from the study prior to documentation of PD was censored at the date of last disease assessment documenting absence of PD. Participants who started a new anticancer treatment prior to documentation of PD were censored at the date of last disease assessment prior to the start of new treatment. The confidence interval (CI) was calculated using the complementary log-log transformation method.
Part A: Confirmed Investigator Determined Progression Free Survival (PFS) According to RECIST v1.1	From first dose of study treatment to the date of PD or clinical PD or censoring whichever occurred first (maximum up to 8.3 months)	PFS: time from start of study treatment to the first documentation of PD by RECIST v1.1 or clinical PD. Participants who do not have PD and are still on study at the time of an analysis or who are removed from the study prior to documentation of PD were censored at the date of last disease assessment documenting absence of PD. Participants who started a new anticancer treatment prior to documentation of PD were censored at the date of last disease assessment prior to the start of new treatment. PD: At least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. Appearance of one or more new lesions was also considered progression. Median was estimated using the Kaplan-Meier method and the CI was calculated using the complementary log-log transformation method.
Part B: Confirmed Investigator Determined PFS According to RECIST v1.1	From first dose of study treatment to the date of PD or clinical PD or censoring whichever occurred first (maximum up to 34.7 months for 1.25 mg/kg and 5.7 months for 1 mg/kg dose level)	PFS: time from start of study treatment to the first documentation of PD by RECIST v1.1 or clinical PD. Participants who do not have PD and are still on study at the time of an analysis or who are removed from the study prior to documentation of PD were censored at the date of last disease assessment documenting absence of PD. Participants who started a new anticancer treatment prior to documentation of PD were censored at the date of last disease assessment prior to the start of new treatment. PD: At least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. Appearance of one or more new lesions was also considered progression. Median was estimated using the Kaplan-Meier method and the CI was calculated using the complementary log-log transformation method.
Part B: Confirmed Investigator Determined PSA-PFS, for Prostate Cancer	From first dose of study treatment to the date of PD or clinical PD or censoring whichever occurred first (maximum up to 5.7 months)	PSA-PFS: time from start of study treatment to first documentation of PSA progression or death due to any cause, whichever occurred first. Participants who do not have PD and are still on study at time of analysis or who are removed from study prior to documentation of PD was censored at date of last disease assessment documenting absence of PD. Participants who started new anticancer treatment prior to documentation of PD were censored at date of last disease assessment prior to the start of new treatment. PD: at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (this included baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must also demonstrate absolute increase of at least 0.5 cm. Appearance of one or more new lesions was also considered progression. Median was estimated using Kaplan-Meier method and CI was calculated using the complementary log-log transformation method.
Part A: Overall Survival (OS)	From first dose of study treatment to the date of death or censoring whichever occurred first (maximum up to 27.5 months)	OS was defined as the time from the start of study treatment to date of death due to any cause. Participants who do not have PD and are still on study at the time of an analysis or who are removed from the study prior to documentation of PD was censored at the date of last disease assessment documenting absence of PD. Participants who started a new anticancer treatment prior to documentation of PD were censored at the date of last disease assessment prior to the start of new treatment. Median was estimated using the Kaplan-Meier method.
Part B: Overall Survival	From first dose of study treatment to the date of death or censoring whichever occurred first (maximum up to 37.5 months for 1.25 mg/kg and 20.9 months for 1 mg/kg dose level)	OS was defined as the time from the start of study treatment to date of death due to any cause. Participants who do not have PD and are still on study at the time of an analysis or who are removed from the study prior to documentation of PD was censored at the date of last disease assessment documenting absence of PD. Participants who started a new anticancer treatment prior to documentation of PD were censored at the date of last disease assessment prior to the start of new treatment. Median was estimated using the Kaplan-Meier method.
Part A: Area Under the Serum Concentration Time Curve Between Days 0 to 21 (AUC21) of Ladiratuzumab Vedotin	AUC21 is reported on Day 21 using PK concentrations assessed at Pre-dose, end of infusion, 2 hour, 4 hour, 48 hour, 168 hour and 336 hour post dose of Cycle 1 (each cycle = 21 days, LV administered on Day 1 of cycle)	Area under the observed concentration-time curve from the time of dosing to Day 21 of LV was calculated by noncompartmental analysis.
Part A: Maximum Serum Concentration (Cmax) According to Antibody-Drug Conjugate (ADC) Pharmacokinetic Parameters	Cmax during Day 1 to 21 post LV administration on Day 1 was reported using PK concentration assessed at Pre-dose, end of infusion, 2 hour, 4 hour, 48 hour, 168 hour and 336 hour post-dose of LV administration on Day 1 (each cycle = 21 days)	Cmax according to ADC pharmacokinetic parameters was reported.
Part A: AUC21 of Total Antibody (TAB)	AUC21 is reported on Day 21 using PK concentrations assessed at Pre-dose, end of infusion, 2 hour, 4 hour, 48 hour, 168 hour and 336 hour post dose of Cycle 1 (each cycle = 21 days, LV administered on Day 1 of cycle)	Area under the observed concentration-time curve from the time of dosing to Day 21 of TAB was calculated by noncompartmental analysis.
Part A: Cmax According to TAB Pharmacokinetic Parameters	Cmax during Day 1 to 21 post LV administration on Day 1 was reported using PK concentration assessed at Pre-dose, end of infusion, 2 hour, 4 hour, 48 hour, 168 hour and 336 hour post-dose of LV administration on Day 1 (each cycle = 21 days)	Cmax according to TAB pharmacokinetic parameters was reported.
Part A: AUC21 of Monomethyl Auristatin E (MMAE)	AUC21 is reported on Day 21 using PK concentrations assessed at Pre-dose, end of infusion, 2 hour, 4 hour, 48 hour, 168 hour and 336 hour post dose of Cycle 1 (each cycle = 21 days, LV administered on Day 1 of cycle)	Area under the observed concentration-time curve from the time of dosing to Day 21 of MMAE was calculated by noncompartmental analysis.
Part A: Cmax According to MMAE Pharmacokinetic Parameters	Cmax during Day 1 to 21 post LV administration on Day 1 was reported using PK concentration assessed at Pre-dose, end of infusion, 2 hour, 4 hour, 48 hour, 168 hour and 336 hour post-dose of LV administration on Day 1 (each cycle = 21 days)	Cmax according to MMAE pharmacokinetic parameters was reported.
Part B: Area Under the Concentration Time Curve Between Day 0 to 7 (AUC7) of ADC	AUC7 is reported at Day 7 using PK concentration assessed at Pre-dose, end of infusion, 2hr, 4hr, 48hr post-dose of LV administration on Day 1; pre-dose PK concentration on Day 8 in Cycle 1 (each cycle=21 days, LV administered on Day 1, 8 and 15 of cycle)	Area under the observed concentration-time curve from the time of dosing to Day 7 of ADC was calculated by noncompartmental analysis.
Part B: Cmax According to ADC Pharmacokinetic Parameters	Cmax during Day 1 to 7 post LV administration on Day 1 was reported using PK concentration assessed at Pre-dose, end of infusion, 2 hr, 4 hr, 48 hr post-dose of LV administration on Day 1 (each cycle = 21 days, LV administered on Day 1, 8 and 15 of cycle)	Cmax according to ADC pharmacokinetic parameters was reported.
Part B: AUC7 of TAB	AUC7 is reported at Day 7 using PK concentration assessed at Pre-dose, end of infusion, 2hr, 4hr, 48hr post-dose of LV administration on Day 1; pre-dose PK concentration on Day 8 in Cycle 1 (each cycle=21 days, LV administered on Day 1, 8 and 15 of cycle)	Area under the observed concentration-time curve from the time of dosing to Day 7of TAB was calculated by noncompartmental analysis.
Part B: Cmax According to TAB Pharmacokinetic Parameters	Cmax during Day 1 to 7 post LV administration on Day 1 was reported using PK concentration assessed at Pre-dose, end of infusion, 2 hr, 4 hr, 48 hr post-dose of LV administration on Day 1 (each cycle = 21 days, LV administered on Day 1, 8 and 15 of cycle)	Cmax according to TAB pharmacokinetic parameters was reported.
Part B: AUC7 OF MMAE	AUC7 is reported at Day 7 using PK concentration assessed at Pre-dose, end of infusion, 2hr, 4hr, 48hr post-dose of LV administration on Day 1; pre-dose PK concentration on Day 8 in Cycle 1 (each cycle=21 days, LV administered on Day 1, 8 and 15 of cycle)	Area under the observed concentration-time curve from the time of dosing to Day 7 of MMAE was calculated by noncompartmental analysis.
Part B: Cmax According to MMAE Pharmacokinetic Parameters	Cmax during Day 1 to 7 post LV administration on Day 1 was reported using PK concentration assessed at Pre-dose, end of infusion, 2 hr, 4 hr, 48 hr post-dose of LV administration on Day 1 (each cycle= 21 days, LV administered on Day 1, 8 and 15 of cycle)	Cmax according to MMAE pharmacokinetic parameters was reported.
Part A: Number of Participants With Positive Post-Baseline Antitherapeutic Antibody (ATA) Incidence	From first ATA draw to last ATA draw (maximum up to 8.8 months)	A positive baseline ATA result was considered positive post-baseline if the post-baseline ATA titer result was at least four times higher than the baseline result.
Part B: Number of Participants With Positive Post-Baseline ATA Incidence	From first ATA draw to last ATA draw (maximum up to 22.1 months for 1.25 mg/kg and 5.1 months for 1 mg/kg)	A positive baseline ATA result was considered positive post-baseline if the post-baseline ATA titer result was at least four times higher than the baseline result.

Trial Locations

Locations (66): FirstHealth of the Carolinas
🇺🇸
Pinehurst, North Carolina, United States
Adventist Health White Memorial
🇺🇸
Los Angeles, California, United States
Northwestern University
🇺🇸
Chicago, Illinois, United States
Comprehensive Cancer Centers of Nevada
🇺🇸
Las Vegas, Nevada, United States
Fort Wayne Medical Oncology and Hematology
🇺🇸
Fort Wayne, Indiana, United States
Gabrail Cancer Center Research, LLC
🇺🇸
Canton, Ohio, United States
Erlanger Oncology and Hematology
🇺🇸
Chattanooga, Tennessee, United States
Taipei Medical University Hospital
🇨🇳
Taipei, Other, Taiwan
Taichung Veterans General Hospital
🇨🇳
Taichung, Other, Taiwan
Valley Hospital, The / Luckow Pavilion
🇺🇸
Paramus, New Jersey, United States
University of Maryland
🇺🇸
Baltimore, Maryland, United States
Ironwood Cancer & Research Centers - Chandler
🇺🇸
Chandler, Arizona, United States
Providence Medical Foundation
🇺🇸
Santa Rosa, California, United States
GenesisCare USA
🇺🇸
Jacksonville, Florida, United States
Seoul National University Bundang Hospital
🇰🇷
Seongnam-si, Other, Korea, Republic of
Carbone Cancer Center / University of Wisconsin
🇺🇸
Madison, Wisconsin, United States
Townsville Cancer Center
🇦🇺
Douglas, Other, Australia
IACT Health
🇺🇸
Columbus, Georgia, United States
HealthPartners Institute
🇺🇸
Saint Louis Park, Minnesota, United States
San Juan Oncology Associates
🇺🇸
Farmington, New Mexico, United States
Stony Brook University Cancer Center
🇺🇸
Stony Brook, New York, United States
Joe Arrington Cancer Research and Treatment Center
🇺🇸
Lubbock, Texas, United States
UT Health East Texas Hope Cancer Center
🇺🇸
Tyler, Texas, United States
Peninsula and South East Oncology
🇦🇺
Frankston, Other, Australia
Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
🇮🇹
Bologna, Other, Italy
ASL 3 Genovese Villa Scassi Hospital
🇮🇹
Genova, Other, Italy
Chonnam National University Hwasun Hospital
🇰🇷
Hwasun, Other, Korea, Republic of
National Cheng-Kung University Hospital
🇨🇳
Tainan, Other, Taiwan
Severance Hospital, Yonsei University Health System
🇰🇷
Seoul, Other, Korea, Republic of
Korea University Guro Hospital
🇰🇷
Seoul, Other, Korea, Republic of
Seoul National University Boramae Medical Center
🇰🇷
Seoul, Other, Korea, Republic of
St. Vincent's Hospital, The Catholic University of Korea
🇰🇷
Suwon-si, Other, Korea, Republic of
Ajou University Hospital
🇰🇷
Suwon-si, Other, Korea, Republic of
The Royal Marsden Hospital
🇬🇧
London, Other, United Kingdom
UCL Cancer Institute
🇬🇧
London, Other, United Kingdom
The Royal Marsden Hospital (Surrey)
🇬🇧
Sutton, Other, United Kingdom
Azienda Ospedaliero Universitaria Careggi
🇮🇹
Firenze, Other, Italy
San Luca Hospital
🇮🇹
Lucca, Other, Italy
Irccs Irst
🇮🇹
Meldola, Other, Italy
Niguarda Ca' Granda Hospital
🇮🇹
Milan, Other, Italy
Fondazione IRCCS San Gerardo dei Tintori
🇮🇹
Monza, Other, Italy
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
🇮🇹
Napoli, Other, Italy
Policlinico Universitario Agostino Gemelli
🇮🇹
Roma, Other, Italy
AOUS Policlinico Le Scotte
🇮🇹
Siena, Other, Italy
The Beatson West of Scotland Cancer Centre
🇬🇧
Glasgow, Other, United Kingdom
Sarah Cannon Research Institute UK
🇬🇧
London, Other, United Kingdom
The Christie NHS Foundation Trust
🇬🇧
Manchester, Other, United Kingdom
Royal Hobart Hospital
🇦🇺
Hobart, Other, Australia
Tennessee Oncology-Nashville/Sarah Cannon Research Institute
🇺🇸
Nashville, Tennessee, United States
Eastern CT Hematology and Oncology Associates
🇺🇸
Norwich, Connecticut, United States
AdventHealth Cancer Institute
🇺🇸
Orlando, Florida, United States
Weill Cornell Medicine
🇺🇸
New York, New York, United States
Decatur Memorial Hospital - Illinois
🇺🇸
Decatur, Illinois, United States
Saint Francis Hospital / Bon Secours - South Carolina
🇺🇸
Greenville, South Carolina, United States
Flinders Medical Centre
🇦🇺
Bedford Park, Other, Australia
Cabrini
🇦🇺
Malvern, Other, Australia
Central Coast Local Health District (Gosford and Wyong Hospitals)
🇦🇺
Gosford, Other, Australia
St Vincents Hospital Sydney
🇦🇺
Sydney, Other, Australia
Istituto Europeo di Oncologia
🇮🇹
Milano, Other, Italy
Dong-A University Hospital
🇰🇷
Busan, Other, Korea, Republic of
National Taiwan University Hospital
🇨🇳
Taipei, Other, Taiwan
Melanoma Institute Australia
🇦🇺
Wollstonecraft, Other, Australia
Seoul National University Hospital
🇰🇷
Seoul, Other, Korea, Republic of
Samsung Medical Center
🇰🇷
Seoul, Other, Korea, Republic of
University of Michigan Comprehensive Cancer Center
🇺🇸
Ann Arbor, Michigan, United States
Providence Portland Medical Center
🇺🇸
Portland, Oregon, United States